Tag: Nabriva Therapeutics US
Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan...
- Principal Repayments Delayed At Least Until January 1, 2022 - Repayment Delay and Recent ATM Activity Extends Cash...
Nabriva Announces Changes to its Board of Directors
DUBLIN, Ireland and FORT WASHINGTON, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged...
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company...
Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.
- SIVEXTRO now available under Nabriva’s National Drug Code - 100% of SIVEXTRO’s net product sales to be recorded by...